EP3721216A1 - Masquage et visualisation consécutive de signaux esr grâce à la combinaison de deux matériaux - Google Patents

Masquage et visualisation consécutive de signaux esr grâce à la combinaison de deux matériaux

Info

Publication number
EP3721216A1
EP3721216A1 EP18815955.2A EP18815955A EP3721216A1 EP 3721216 A1 EP3721216 A1 EP 3721216A1 EP 18815955 A EP18815955 A EP 18815955A EP 3721216 A1 EP3721216 A1 EP 3721216A1
Authority
EP
European Patent Office
Prior art keywords
phases
phase
esr
body according
paramagnetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18815955.2A
Other languages
German (de)
English (en)
Inventor
Norbert Windhab
Andreas Karau
Peter Hölig
Benedikt Hartwig
Julia Lyubina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Operations GmbH
Original Assignee
Evonik Operations GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Operations GmbH filed Critical Evonik Operations GmbH
Publication of EP3721216A1 publication Critical patent/EP3721216A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/10—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using electron paramagnetic resonance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4866—Evaluating metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/60—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using electron paramagnetic resonance

Definitions

  • the invention relates to a body having a plurality of phases which have different electron spin resonance spectra.
  • Subgroups with increasing atomic number of the chemical element which is the core atom associated with the localized electron spin, are increasingly influenced by spin-orbit coupling effects.
  • the material scientist is therefore also familiar with micro- and macroscopic spin-lattice systems up to metallic conductor bodies.
  • ESR electron spin resonance
  • ESR spectroscopy is basically only accessible to systems with unpaired electrons, such as radical systems, paramagnetic transition metals, band magnets, and semiconductors.
  • unpaired electrons such as radical systems, paramagnetic transition metals, band magnets, and semiconductors.
  • the resonant electron spin may be subject to complex interactions, for example between electron and nuclear spin, and / or influenced by spatial symmetry.
  • this causes complex, often difficult to interpret, ESR spectra.
  • Formulations predict the behavior of spin system, the moment giving "probe”, the aggregate aggregate as well as the legalistic-regular applicability hard.
  • the intensity of the ESR signal which is equivalent to the integral of the absorption signal, is directly proportional to the spontaneous magnetization M s of the sample, as the article by B. Heinrich and JF Cochran in Advances in Physics 42 (1993), 523, sets forth.
  • the linewidth of the ESR signal follows a dependence in the form of
  • Ki is the magnetocrystalline anisotropy constant, cf. Ya.G. Dorfman, J. Exp. Theor. Phys. 48 (1965), 715.
  • the magnetic shape anisotropy also has a significant influence on the shape and position of the ESR signal. Since the magneto-crystalline anisotropy of the known ferro- or ferrimagnetic materials in the range of 10 3 to 10 ® J / m are 3, is accordingly an ESR linewidth
  • the critical size of the particles is determined by magnetocrystalline anisotropy. In magnetite, the critical particle size is about 14 nm, cf. G. Vallejo-Fernandez et al., J. Phys. D: Appl. Phys. 46 (2013), 312001.
  • Magnetite nanoparticles with particle sizes of and below 14 nm may have relatively narrow ESR lines characteristic of paramagnetic and superparamagnetic particles. discussed in the article by J. Salado et al., J. Non-Crystalline Solids 354 (2008), 5207, and R. Berger, J. Magn. Magn. Mater. 234 (2001), 535.
  • Combinations of different systems such as in the form of mixtures, compounds or compositions generally from different macroscopic or microscopic phases for the respective composition characteristic ESR spectra provide.
  • compositions of at least two materials have been found in which at least one material outside the composition in its pure form would provide a characteristic ESR spectrum. However, in the composition with at least one other material, this same ESR spectrum is surprisingly greatly attenuated or completely gone.
  • the subject of the invention is therefore a body which has several phases and is absorbed by the human or animal organism or is located within the organism, which is characterized in that the body has at least two phases with a different electron spin resonance spectrum.
  • the article has the advantage of being limited in non-physiological or questionable toxicological in its vital function by radiation or toxicity of the material.
  • At least one of the phases advantageously has itinerant or localized magnetism.
  • ESR spectra of rare earths are found to be less well suppressed, whereby, depending on the combination, the body according to the invention shows a weakening of the ESR spectrum or a superposition of different ESR spectra.
  • At least one phase of the inventive body has purely paramagnetic centers, preferably S radicals, preferably selected from
  • Ultramarine It may be particularly advantageous to select superparamagnetic particles instead of the ultramarine, preferably containing or consisting of magnetite or maghemite or pyrite or iron-containing compounds such as amethyst. For such particles, a similar ESR signal is found.
  • at least one phase of the body according to the invention has at least one collective ordering state, which may be ferro-, ferri-, and / or antiferromagnetic. Most preferably, these iron-oxygen compounds.
  • At least one phase of magnetite or a phase of the Fe-0 system is very particularly preferred.
  • the mentioned phases are harmless substances especially for the human or animal organism.
  • such selected phases may be expressed as tablets formulation.
  • the phases can also be readjusted in particle dispersions. Again, it is surprising that a pharmaceutical formulation can thus be provided in a simple manner, since it is precisely magnetite or a material having Fe-O phases which is very well tolerated by the human organism and would also be useful in human medicine
  • the body according to the invention could therefore also be used safely in the gastrointestinal area, because the body has neither highly toxic substances nor harmful radicals.
  • the invention also relates to the use of the body according to the invention, wherein the ESR spectra stored in a data storage device, and the stored data preferably on the receipt of a request signal out
  • inventive body for the measurement of ESR spectra only very small
  • At least one phase is enveloped by at least one further phase.
  • one phase envelops a further phase as a thin film.
  • the thickness of the film and the phases may be selected such that the ESR spectrum of the inner, enveloped phase is completely masked by the ESR spectrum of the outer, enveloping phase.
  • the decomposition of the enveloping phase causes the ESR signal of the coated phase to become more pronounced as a function of time. This simple time dependence is another beneficial property of the body.
  • magnetite particles in at least one phase of the body the inventors believe, without being bound to any particular theory, that the ESR spectrum is caused not only by intrinsic magnetic properties but also by dipole interactions between magnetite particles could be.
  • the interactions are preferably influenced by the shape of the particles, for example ball, needle, cube, in general the spatial distribution of the magnetite, for example film.
  • a ferromagnetic and a free-radical phase for example an ultramarine phase
  • a free-radical phase for example an ultramarine phase
  • the decomposition of the body in the organism can be specifically attributed to the decomposition process.
  • the body according to the invention has at least three phases, one phase preferably being paramagnetic, preferably selected from (phen) CuCl 2.
  • the ESR line shape is more complex, and one obtains a time-resolved behavior in decomposing the mixture of phases, for example, in the decomposition of the body during the metabolic process in the organism, which is detected with a time-dependence of the ESR spectrum. It is a progressive decomposition documentable.
  • magnetic, paramagnetic and radical phases can be combined. If such a composite body decomposes in the organism, appears with the decomposition-induced disappearance of the magnetic phase or its detachment from the Body another, so-called "final" ESR line shape, which differs significantly from the ESR line shape of the undecomposed body according to the invention.
  • Such decomposition processes are beneficial in non-therapeutic processes, such as in the context of personal, non-medically motivated nutrition issues or dietary habits.
  • the decomposition processes are also the goal of, for example, medical implants, in their functional coatings and especially oral dosage forms of
  • nutraceutical, dietetic or therapeutic formulations such as e.g. Capsules, tablets, films and granules and multiparticulate dosage forms of
  • Solubility particularly preferably pH- and time-dependent solubility of such auxiliaries and excipients are preferred.
  • it is particularly the hydrolysis that leads to the desired absorption of matrices and coatings.
  • examples include the permissible materials and polymers Eudragit® methacrylates and Resomer® polyester, modified starches such as HMPC, HMPC-AS or polylactites and co-glycolites or co-caprolactone for surgical material, as well as resorbable medical coatings or implants. In doing so, such
  • Isolatorpolymere especially medico-technical polymers themselves carry paramagnetic centers, such as e.g. arising during sterilization irradiation by means of e-beam or g-irradiation.
  • the inventive body has at least one phase with at least one medico-technical polymer having a paramagnetic center, preferably isolated radicals.
  • the appearance of the final ESR line shape can be interpreted as a fingerprint of the body during decomposition in the organism. This will be explained in more detail in Example 2 and Figure 3.
  • the invention also relates to the use of the body according to the invention, which has at least three phases, for the monitoring of decomposition processes in
  • room temperature is understood in the context of the invention, an ambient temperature of 20 ° C.
  • Example 1 Inventive body containing ultramarine blue and magnetite.
  • ESR spectra were recorded in the X-band (9.5 GHz) at room temperature and a microwave energy of 6.3 mW, at a modulation frequency of 100 kHz and an amplitude up to 5 Gauss.
  • FIG. 1a shows ESR spectra on various mixtures of MAG and UB.
  • the S - radical signal was barely recognizable because of the strong magnetic interaction between MAG and S - radicals.
  • FIG. 2 shows ESR spectra obtained on thin layers of UB and MAG on adhesive strips.
  • the ESR signals of the layers coincide with MAG or UB with the ESR signals of the pure components MAG and UB.
  • Hint - Happl-NM where M is the magnetization, N is a demagnetization factor and H appi is the external magnetic field used for spectroscopy.
  • the demagnetization is dependent on the geometry of the M-containing particles or substance as well as the global shape of the body, which consists of such particles or substance dependent. In the form of a layer, for example, which has led to the spectrum in Fig. 2, one finds a much stronger demagnetizing field when the external magnetic field is applied perpendicular to the layer surface, as is caused by spherical or cubic particles or body. N may be suspected close to 1.
  • N «1/3 For spherical or cubic particles or bodies, which are not arranged in particular as a layer, N «1/3 can be applied. It is also suspected that the
  • demagnetizing field causes the shift of the ESR spectra due to a change of magnetostatic interaction when the layers containing magnetite and ultramarine are stacked on each other, as the above-mentioned dipole interactions in the case that magnetite and ultramarine are mixed together.
  • Example 2 Body containing phen (CuCl2) and ultramarine blue.
  • Example 2 the mixture was provided in place of MAG with paramagnetic dichloro (1, 10-phenanthroline) Cu M (phen (CuCl 2)) complex and ultramarine blue in the weight ratio 1: 1.
  • Example 3 Inventive body suspended as a tablet in water.
  • Methylcellulose pressed into a tablet by the mixture was exposed during 2 min to a pressure of 10 bar.
  • the tablet thus obtained was crushed and suspended in water in a beaker.
  • samples of the suspension were filled into a glass capillary after different times.
  • Various ESR spectra were obtained as a function of time, shown in Figure 6, with the line shape (a) the not yet suspended tablet and the line shape (b) the signal of the advanced suspension tablet.
  • the apparent total intensity of the ESR signal demonstrates the altered content of suspended solid over time.
  • the monitoring of decomposition processes according to the invention is therefore also possible for a simple dissolution of the body according to the invention.
  • the line shape (c) in FIG. 6 shows the magnetite-free ESR signal for comparison.
  • the pure magnetite showed the typical broad asymmetric singlet for
  • the ESR spectrum of ultramarine contained a narrow isotropic signal S3 - was attributable radical, see Figure 5. It was typical for purely paramagnetic centers.

Landscapes

  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Cigarettes, Filters, And Manufacturing Of Filters (AREA)

Abstract

L'invention concerne un corps à plusieurs phases qui présentent différents spectres de résonance de spin électronique qui ne résultent pas individuellement de la simple combinaison des spectres ESR de chaque phase.
EP18815955.2A 2017-12-04 2018-11-23 Masquage et visualisation consécutive de signaux esr grâce à la combinaison de deux matériaux Withdrawn EP3721216A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17205099 2017-12-04
PCT/EP2018/082302 WO2019110321A1 (fr) 2017-12-04 2018-11-23 Masquage et visualisation consécutive de signaux esr grâce à la combinaison de deux matériaux

Publications (1)

Publication Number Publication Date
EP3721216A1 true EP3721216A1 (fr) 2020-10-14

Family

ID=60856841

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18815955.2A Withdrawn EP3721216A1 (fr) 2017-12-04 2018-11-23 Masquage et visualisation consécutive de signaux esr grâce à la combinaison de deux matériaux

Country Status (10)

Country Link
US (1) US11666668B2 (fr)
EP (1) EP3721216A1 (fr)
JP (1) JP2021505866A (fr)
KR (1) KR102573045B1 (fr)
CN (1) CN111566474A (fr)
BR (1) BR112020011294A2 (fr)
CA (1) CA3084087A1 (fr)
IL (1) IL275036A (fr)
MX (1) MX2020005764A (fr)
WO (1) WO2019110321A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220016267A (ko) * 2019-06-04 2022-02-08 에보니크 오퍼레이션즈 게엠베하 제품의 고유 식별 및 인증

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005189219A (ja) * 2003-12-25 2005-07-14 Shoichi Ri 生体内フリーラジカル分解能の判定方法及び判定装置
US20060019172A1 (en) * 2004-03-25 2006-01-26 Hiroyuki Ohtaki Volume hologram resin composition, surface relief hologram resin composition, and hologram layer, hologram transfer foil and brittle hologram label using the same
EP1960001A2 (fr) * 2005-12-08 2008-08-27 Koninklijke Philips Electronics N.V. Systeme et procede permettant de surveiller la liberation de medicaments in vivo par rmn amelioree par effet overhauser
JP4297170B2 (ja) * 2007-02-23 2009-07-15 セイコーエプソン株式会社 電気泳動表示シート、電気泳動表示装置、電気泳動表示装置の製造方法および電子機器
WO2009077356A2 (fr) * 2007-12-14 2009-06-25 Basf Se Compositions d'écran solaire comprenant des pigments de couleur
JP4907591B2 (ja) * 2008-04-08 2012-03-28 株式会社日立製作所 Ｅｓｒ用造影剤とその製造方法
US9925278B2 (en) * 2008-10-23 2018-03-27 Koninklijke Philips N.V. Molecular imaging
BR112012004967B8 (pt) 2009-09-03 2022-07-05 Evonik Roehm Gmbh forma de dosagem oral, compreendendo pelo menos um agente biologicamente ativo, substâncias auxiliares da formulação e partículas magnetizáveis, seu uso e seu método de produção
DE102011089334A1 (de) 2011-12-21 2013-06-27 Evonik Röhm Gmbh Detektionssystem zur Erfassung magnetischer Objekte im menschlichen Organismus
ES2439167B1 (es) * 2012-06-21 2014-11-17 Consejo Superior De Investigaciones Científicas (Csic) Compuestos con funcionalidad magnética, implantes o geles derivados de ellos, y el uso de ambos para determinar la actividad enzimática de una enzima
DE102013211703A1 (de) 2013-06-20 2014-12-24 Evonik Röhm Gmbh Personalisiertes Detektionssystem zur Erfassung magnetischer Objekte im menschlichen Organismus
JP5975002B2 (ja) * 2013-09-13 2016-08-23 ニチレイマグネット株式会社 カラー磁性膜構造

Also Published As

Publication number Publication date
US20210164927A1 (en) 2021-06-03
JP2021505866A (ja) 2021-02-18
KR20200093023A (ko) 2020-08-04
KR102573045B1 (ko) 2023-09-01
BR112020011294A2 (pt) 2020-11-17
MX2020005764A (es) 2020-08-20
CN111566474A (zh) 2020-08-21
WO2019110321A1 (fr) 2019-06-13
US11666668B2 (en) 2023-06-06
IL275036A (en) 2020-07-30
CA3084087A1 (fr) 2019-06-13

Similar Documents

Publication Publication Date Title
Almessiere et al. Ce–Nd Co-substituted nanospinel cobalt ferrites: an investigation of their structural, magnetic, optical, and apoptotic properties
Albino et al. Role of Zn2+ substitution on the magnetic, hyperthermic, and relaxometric properties of cobalt ferrite nanoparticles
Millan et al. Surface effects in maghemite nanoparticles
Namanga et al. Synthesis and Magnetic Properties of a Superparamagnetic Nanocomposite “Pectin‐Magnetite Nanocomposite”
EP3981016B1 (fr) Identification et authentification univoques de produits
Sharma et al. Synthesis of chromium substituted nano particles of cobalt zinc ferrites by coprecipitation
Nedkov et al. Surface oxidation, size and shape of nano-sized magnetite obtained by co-precipitation
Rasouli et al. Ultrasmall superparamagnetic Fe3O4 nanoparticles: honey-based green and facile synthesis and in vitro viability assay
Jing et al. Synthesis and characterization of monodisperse hematite nanoparticles modified by surfactants via hydrothermal approach
De Toro et al. Controlled close-packing of ferrimagnetic nanoparticles: An assessment of the role of interparticle superexchange versus dipolar interactions
Dorniani et al. In vitro sustained release study of gallic acid coated with magnetite‐PEG and magnetite‐PVA for drug delivery system
Yan et al. Structure and magnetic properties of nickel–zinc ferrite microspheres synthesized by solvothermal method
Naik et al. Gamma radiation roused lattice contraction effects investigated by Mössbauer spectroscopy in nanoparticle Mn–Zn ferrite
Seemann et al. Magnetic heating properties and neutron activation of tungsten-oxide coated biocompatible FePt core–shell nanoparticles
Morales et al. Size selected synthesis of magnetite nanoparticles in chitosan matrix
Arshad et al. Synthesis and characterization of cobalt ferrites as MRI contrast agent
Saidani et al. Surface and interparticle interactions effects on nano-cobalt ferrites
EP3721216A1 (fr) Masquage et visualisation consécutive de signaux esr grâce à la combinaison de deux matériaux
DE112014001699T5 (de) Für Magnetsensordetektion nützliche magnetische Nanopartikel speziell bei Biosensoranwendungen
Mercado et al. Yerba Mate applications: Magnetic response of powders and colloids of iron oxide nanoparticles coated with Ilex paraguariensis derivatives
Islam et al. Synthesis of monodisperse and high moment nickel–iron (NiFe) nanoparticles using modified polyol process
Noh et al. Crystallographic and magnetic properties of Co, Zn, Ni-Zn substituted nano-size manganese ferrites synthesized by sol-gel method
Mdlalose et al. Chitosan coating by mechanical milling of MnFe2O4 and Mn0. 5Co0. 5Fe2O4: Effect of milling
Markovich et al. Particle size effects on charge ordering and exchange bias in nanosized Sm0. 43Ca0. 57MnO3
Moeen et al. Synthesis and rheological properties of nickel‐zinc ferrite polymer nanocomposites

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200527

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40029175

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20211116

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230906

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240117